TrialCancer chemotherapy and pharmacology2021

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.

Hong Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.